Get your free personalized podcast brief

We scan new podcasts and send you the top 5 insights daily.

Fizazi reports the phase 2 A-DREAM trial, where patients with dramatic responses after 18–24 months of ADT and at least a year of an AR pathway inhibitor stopped treatment. About 40% were treatment-free and eugonadal at 18 months, with a median roughly two years before progression. Formal phase 3 testing is ongoing.

Related Insights

After years of treatment intensification, a new focus in metastatic hormone-sensitive prostate cancer is de-escalation. Trials like ADREAM are evaluating planned treatment interruptions for patients with excellent responses, aiming to provide 'treatment-free intervals' that improve quality of life without sacrificing efficacy.

The EMBARK trial showed that enzalutamide monotherapy was superior to standard ADT monotherapy for metastasis-free survival. This suggests potent AR antagonism may be a more effective strategy than simply depleting the testosterone ligand, challenging the long-held dogma of ADT being the fundamental building block for systemic prostate cancer therapy.

The EMBARC study's "intermittent" arm is misleading. It tested only one treatment-free period, limited to extreme responders who achieved an undetectable PSA. Therapy was then resumed continuously until progression, making it more akin to a trial for metastatic hormone-sensitive disease with a single break, not a model for real-world, multi-cycle intermittent therapy.

In castration-resistant states, prostate cancer cells often amplify their androgen receptors (AR) to survive low testosterone levels. Bipolar androgen therapy exploits this by introducing a massive surge of testosterone. This "shocks" the over-amplified AR system, causing it to regress and disrupting downstream tumor growth pathways.

The EMBARK study demonstrates that an intermittent approach to androgen deprivation therapy (ADT), especially with combination ADT and enzalutamide, can provide patients with low-volume metastatic disease a median of 1.5 years off therapy, improving quality of life without compromising outcomes.

Even when an ARPI is no longer effective as a standalone therapy, continuing it may be beneficial. By maintaining pressure on the androgen receptor pathway, the drug can upregulate downstream targets like PSMA, potentially enhancing the efficacy of subsequent PSMA-targeted therapies like radioligands or ADCs.

When patients with PSA recurrence are treated intermittently with ADT regimens, their disease may behave differently upon relapse. The PSA doubling time after a treatment break can become longer and more favorable, suggesting the therapy may alter the tumor's biology rather than just temporarily suppressing it.

A VA study using real-world data confirms that androgen receptor pathway inhibitors (ARPIs) combined with ADT significantly improve survival in elderly (>75), frail, and high-comorbidity prostate cancer patients. This evidence directly addresses clinician hesitancy to treat these vulnerable populations with standard-of-care combination therapy.

Unlike older studies with ADT monotherapy, the EMBARC and ADREEM trials show that with modern drug combinations and PSMA PET imaging, intermittent therapy is a viable strategy. This allows for safe treatment breaks that improve quality of life by enabling testosterone recovery.

The IMbark trial demonstrated that an ARPI (enzalutamide), either alone or with ADT, outperformed ADT monotherapy in high-risk patients. This pivotal finding raises the question of whether giving ADT alone in any setting, such as with radiation for localized disease, is now an outdated and inferior approach.